Journals / Bezmiâlem Science / 2018 / Cilt: 6 - Sayı: 3

Progresyona Kadar Devamlı Azasitidin Tedavisi, Yaşlı Akut Miyeloid Lösemililerde Uzun Süreli Hastalık Kontrolü Sağlayabilir

Indefinite Azacitidine Treatment Until Progression May Provide Long-Term Disease Control in Elderly Patients with Acute Myelogenous Leukemia

Pages
233–235
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Yüksek blast sayılı yaşlı AML hastalarında azasitidin tedavisine devam edilmesi sağ kalım sü- resini artırmaktadır.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Yaşlı hastalarda akut myeloid löseminin (AML) prognozu kö- tüdür.
📊
Key Findings & Data:İki ve 5 yıllık ortalama sağ kalım oranları sırasıyla %10 ve %2’dir.
💡
Conclusion & Impact:Yüksek blast sayılı yaşlı AML hastalarında azasitidin tedavisine devam edilmesi sağ kalım sü- resini artırmaktadır.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Yaşlı hastalarda akut myeloid löseminin (AML) prognozu kö- tüdür. İki ve 5 yıllık ortalama sağ kalım oranları sırasıyla %10 ve %2’dir. Burada amacımız uzun süreli azasitidin tedavisi ile sağ kalımın uzadığının gösterilmesidir. Yüksek blast sayılı 3 yaşlı AML hastasında 4. Ve 6. Kürler sonunda tam remisyon elde edildi. Birinci olguda 4 kür tedavi ile remisyon elde edil- dikten sonra tedavisiz izlendi. Bir yıl sonunda nüks gelişen hasta pnömoni nedeniyle öldü. İkinci ve 3. olguda sırasıyla 4 ve 6 kür sonunda tam remisyon elde edildi. İkinci olguda 16. Kür sonunda nüks gelişti. Üçüncü olgu ise tedavisinin 16. Ayında halen remisyonda izlenmektedir. Yüksek blast sayılı yaşlı AML hastalarında azasitidin tedavisine devam edilmesi sağ kalım sü- resini artırmaktadır.

Özet

The prognosis of acute myelogenous leukemia (AML) is poor in elderly patients. The mean survival rates at second and fifth years for AML were 10% and 2%, respectively. Here our aim was to demonstrate that the survival rate can be prolonged by long-term azacitidine (AZA) treatment. Complete remission was achieved at the end of the fourth and sixth courses of AZA treatment in three elderly patients with AML with a high blast count. The first patient was followed without any treatment after getting com- plete remission with four courses of AZA, and at the end of 1 year follow-up, the patient died due to pneumonia. Complete re- mission was obtained in the second and third patients after four and six courses of AZA, respectively. Second patient is still being followed up in complete remission at the end of the 20th course of AZA. Recurrence occurred at the end of the 16th AZA course in the third patient and he died after 20 months of the treatment. In elderly patients with AML with a high blast count, the con- tinuation of AZA treatment improves the overall survival rates.

🔖

Cite This Article

ESER, A., SEZGİN, A., KARA, O., BOZKURT, S. U. (2018). Progresyona Kadar Devamlı Azasitidin Tedavisi, Yaşlı Akut Miyeloid Lösemililerde Uzun Süreli Hastalık Kontrolü Sağlayabilir. Bezmiâlem Science, Cilt: 6 - Sayı: 3, 233–235. https://ajindex.com/articles/150728

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002; 52: 363-71. [CrossRef ] Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The out- comes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002; 162: 1597-603. [CrossRef ] National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. Ver- sion 1, 2015. Available from: http://www.nccn.org/profession- als/physician_gls/pdf/aml.pdf Kantarjian H, O’brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk my- elodysplastic syndrome: predictive prognostic models for out- come. Cancer 2006; 106: 1090-8. [CrossRef ] Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002; 99: 4343-9. [CrossRef ] Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, et al. A randomized study of clofarabine versus clo- farabine plus low-dose cytarabine as front-line therapy for pa- tients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112: 1638- 45. [CrossRef ] Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of high- er-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-32. [CrossRef ] Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Staud- er R, Pfeilstocker M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Aus- trian Azacitidine Registry of the AGMT-Study Group. Ann Hematol 2014; 93: 1825-38. [CrossRef ] Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Hol- land JC, Odchimar-Reissig R, et al. Randomized controlled tri- al of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-40. [CrossRef ] Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54. [CrossRef ]